BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype-Phase 2a results. Meeting Abstract

cited authors

  • Zhang, Jingsong; Aggarwal, Rahul Raj; Tagawa, Scott T.; Linch, Mark David; Petrylak, Daniel P.; Costin, Dan; De Bono, Johann S.; Jones, Robert; Karsh, Lawrence Ivan; Zhu, Xinhua; Borderies, Pascal; Deshpande, Rashmi Majali; O'Neill, Vincent; Monk, Paul

Publication Date

  • February 20, 2022

webpage

published in

category

volume

  • 40

issue

  • 6